福瑞股份收盘上涨1.12%，滚动市盈率92.42倍，总市值91.68亿元

Group 1 - The core viewpoint of the article highlights the performance and valuation of Furuya Co., Ltd. in the medical device industry, noting its high PE ratio compared to industry averages [1] - As of June 9, Furuya's closing price was 34.42 yuan, with a rolling PE ratio of 92.42 times and a total market capitalization of 9.168 billion yuan [1] - The average PE ratio for the medical device industry is 50.64 times, with a median of 37.05 times, placing Furuya at the 105th position in the industry ranking [1] Group 2 - On June 9, Furuya experienced a net inflow of main funds amounting to 16.1078 million yuan, although it has seen a total outflow of 87.8763 million yuan over the past five days [1] - Furuya's main business includes the production and sales of drugs in the liver disease sector, development and sales of diagnostic equipment, and related medical services, with its primary product being the Compound Turtle Shell Soft Liver Tablets [1] - The latest quarterly report for Q1 2025 shows Furuya achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1]